Special Issue "Hepatitis and Vaccines"
Deadline for manuscript submissions: 31 December 2021.
2. Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia
3. Disease Elimination Program, Burnet Institute, Melbourne VIC, 3004, Australia
4. Department of Epidemiology and Preventive Medicine, Monash University, Clayton, VIC 3800, Australia
Interests: viral hepatitis; liver cancer; public health; epidemiology; biomarkers
The WHO has set elimination targets to achieve by 2030 to reduce the global burden of morbidity and mortality due to viral hepatitis. Prevention strategies, including vaccination, remain the cornerstone of this goal. There is a highly effective vaccine against the hepatitis B virus; however, timely delivery of the birth dose remains a major challenge worldwide. To overcome this hurdle, novel delivery devices and protocols such as delivery outside of the “cold chain” have been explored but not widely implemented. Currently, there is no effective vaccine available for hepatitis C, yet important work continues in this field. Advances in vaccine technology made through the development of vaccines against SARS-CoV-2 will further catalyze novel approaches to viral hepatitis vaccination development. Vaccine technology is also being explored as a treatment option in viral hepatitis and related liver cancer. However, significant work must be undertaken to ensure equitable, cost-effective, and affordable delivery of viral hepatitis vaccination to achieve the WHO elimination goals.
This Special Edition of Vaccines will cover topics relevant to vaccination in viral hepatitis, including novel vaccine delivery strategies, hepatitis C vaccine development, the role of therapeutic vaccines, and the modeled impact and cost-effectiveness of vaccination strategies to achieve viral hepatitis elimination.
Dr. Jessica Howell
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- viral hepatitis
- hepatitis B
- hepatitis C
- birth dose
- cold chain